Incontinence Neuromodulation Market
Number of pages: 100 | Report Format: PDF | Published date: April 14, 2023
Historical Years – 2021 | Base Year – 2022 | Forecasted Years – 2023-2031
|
Report Attribute |
Details |
|
Market Size Value in 2022 |
US$ 1.30 billion |
|
Market Size Value in 2031 |
US$ 3.04 billion |
|
CAGR |
11.2% |
|
Base Year For Estimation |
2022 |
|
Forecast Period |
2023 to 2031 |
|
Historical Year |
2021 |
|
Segments Covered |
Product Type, Application, End User, and Region |
|
Regional Scope |
North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa |
According to the deep-dive market assessment study by Growth Plus Reports, the global incontinence neuromodulation market was valued at US$ 1.30 billion in 2022 and is expected to register a revenue CAGR of 11.2% to reach US$ 3.04 billion by 2031.
Incontinence Neuromodulation Market Fundamentals
Incontinence neuromodulation is a medical treatment involving electrical stimulation to modify the function of the nerves that control the bladder or bowel. This technique treats urinary or fecal incontinence, characterized by the involuntary loss of urine or stool. Incontinence neuromodulation involves implanting a device, such as sacral neuromodulation, into the body to deliver electrical impulses to the nerves that control bladder or bowel function. The sacral neuromodulation implant can help regulate nerve signals and improve the patient’s ability to control their bladder or bowel function.
[12]
Incontinence Neuromodulation Market Dynamics
The prevalence of urinary incontinence and fecal incontinence is increasing globally, particularly among the aging population. This is driving the demand for effective and long-term solutions for the treatment of urinary incontinence and fecal incontinence, such as neuromodulation therapies. As per a study published in the European Journal of Obstetrics & Gynecology and Reproductive Biology, the prevalence of urinary incontinence ranged from 20.3% to 54.5% globally. The development of more advanced neuromodulation devices is driving the incontinence neuromodulation market revenue growth. Advancements such as rechargeable batteries, smaller devices, and wireless connectivity make these devices more accessible and user-friendly. There is growing awareness of the benefits of neuromodulation therapies among patients and healthcare professionals. Neuromodulation therapies are effective in treating urinary incontinence, and as more patients become aware of this, the demand for these therapies is increasing.
There is a rise in the demand for minimally invasive procedures that offer faster recovery times and reduced risks. Neuromodulation therapies are a minimally invasive option for treating urinary incontinence, making them attractive to many patients. Additionally, the increasing adoption of sacral nerve stimulation as it is currently the most widely used neuromodulation technique for the treatment of urinary incontinence. The sacral neuromodulation procedure involves implanting small devices that deliver electrical stimulation to the sacral nerves, which control bladder function. The growing healthcare expenditure in developed and developing countries is enabling patients to access more advanced treatment options, such as neuromodulation therapies. Furthermore, various countries are implementing favorable reimbursement policies for neuromodulation therapies, making them more accessible to patients. This is also expected to boost the incontinence neuromodulation market revenue growth.
However, sacral neuromodulation side effects such as wound infection, bruising, urinary tract infection (UTI), pain, and difficulty passing urine restricts the incontinence neuromodulation market revenue growth. Neuromodulation therapies require specialized skills and training, and there is a shortage of skilled professionals who can perform these procedures. This can limit the availability of neuromodulation therapies in certain regions, hindering the demand for incontinence neuromodulation. Moreover, the high cost related to neuromodulation is also cramping the incontinence neuromodulation market revenue growth.
Incontinence Neuromodulation Market Ecosystem
The global incontinence neuromodulation market is analyzed from four perspectives: product type, application, end-user, and region.
Incontinence Neuromodulation Market by Product Type
[34]
Based on the product type, the global incontinence neuromodulation market is segmented into external and implantable.
The implantable neuromodulation segment accounted for the largest incontinence neuromodulation market revenue share in 2022. Implantable neuromodulation provides long-term relief for incontinence symptoms, as the implanted device can provide continuous or intermittent stimulation to the nerves that control bladder or bowel function. This can improve urinary or fecal control and reduce incontinence episodes, leading to a better quality of life for patients. Implantable neuromodulation offers a more targeted and personalized treatment approach, as the device can be programmed to deliver specific patterns of electrical impulses based on the patient’s needs. This customization can result in more effective and efficient symptom relief than other neuromodulation forms. Implantable neuromodulation devices have become increasingly sophisticated and user-friendly, with smaller sizes, longer battery life, and wireless programming capabilities. This has made the devices more convenient and easier for patients and healthcare providers, leading to wider adoption and higher patient satisfaction. There is a growing body of clinical evidence supporting the safety and efficacy of implantable neuromodulation for incontinence, which has helped to increase its acceptance among healthcare providers and patients.
The external neuromodulation segment is expected to register a lucrative revenue CAGR during the forecast period. External neuromodulation is a non-invasive treatment option that does not require surgery or implantation of a device. This can make it a more attractive option for patients who are hesitant to undergo invasive procedures, such as the implantation of a device. External neuromodulation is relatively easy to administer and can be performed outpatient. The therapy involves applying a small electrical current to the skin overlying the nerves that control bladder or bowel function using a small device such as a patch or a belt. This ease of use can make the therapy more accessible and convenient for patients. External neuromodulation for incontinence is becoming accepted among medical professionals and patients thanks to a growing amount of clinical evidence demonstrating its efficacy and safety. Also, as a result, external neuromodulation therapy is now more widely covered by insurance.
Incontinence Neuromodulation Market by Application
Based on the applications, the global incontinence neuromodulation market is segmented into urinary incontinence and fecal incontinence. The urinary incontinence segment is further sub-segmented into urge incontinence, overflow incontinence, and others.
The urinary incontinence segment dominated the incontinence neuromodulation market with the largest revenue share. Urinary incontinence is the most common type of incontinence. It is particularly prevalent among women and the elderly, the primary target for neuromodulation therapy. Urinary incontinence is the most studied and established indication for neuromodulation therapy. A vast body of clinical evidence supports the safety and efficacy of neuromodulation therapy for urinary incontinence. Neuromodulation therapy has few side effects, making it a safe and effective treatment option for urinary incontinence, increasing the demand for neuromodulation therapy for treating urinary incontinence. Unlike other treatments, such as medication or surgery, neuromodulation therapy does not require systemic drug delivery or major surgery, which can result in complications. Moreover, neuromodulation therapy has a high success rate in treating urinary incontinence, fueling segmental revenue growth.
The fecal incontinence segment accounts for a considerable incontinence neuromodulation market revenue share in 2022 due to the prevalence and impact of fecal incontinence as a medical condition. Fecal incontinence is a common problem affecting a large population worldwide and can significantly impact an individual’s quality of life, social functioning, and psychological well-being. According to the National Center for Biotechnology Information, the prevalence of fecal incontinence ranges from 2% to 21%. According to similar reports, the prevalence of fecal incontinence is 7% in women under 30, and it will increase to 22% by the seventh decade. Prevalence in geriatric patients is estimated to range from 10% to 25% among hospitalized patients and 25% to 35% among residents of nursing homes. Neuromodulation has emerged as a promising treatment option for fecal incontinence, offering a non-invasive or minimally invasive approach that can significantly improve bowel control and quality of life for many individuals. As a result, there is a growing demand for neuromodulation devices and therapies for fecal incontinence, which has contributed to the revenue growth of the fecal incontinence segment in the incontinence neuromodulation market.
Incontinence Neuromodulation Market by End User
Based on the end users, the global incontinence neuromodulation market is segmented into hospitals, ambulatory surgical centers, and others.
The hospital segment accounted for a significant revenue share of the incontinence neuromodulation market. Hospitals are often equipped with specialized medical personnel, such as urologists, gynecologists, and specialized nurses, who are trained in performing these procedures and managing any potential complications. This expertise and experience are critical for ensuring the safety and efficacy of the procedures. Hospitals typically have access to more advanced equipment and technology, such as imaging tools and surgical suites, which can improve incontinence neuromodulation procedures’ accuracy and success rates. This can result in better patient outcomes and higher patient satisfaction. Hospitals often have a larger patient base, which can result in higher demand for incontinence neuromodulation services, propelling segmental revenue growth.
The ambulatory surgical center’s segment accounted for a considerable revenue share of the incontinence neuromodulation market. Ambulatory surgical centers are designed to provide same-day surgical care, which can be more convenient and cost-effective for patients than traditional hospital-based care. Ambulatory surgical centers can offer a more personalized and efficient patient experience, with shorter wait times and more flexible scheduling. This can appeal to patients who prefer a more convenient and streamlined experience and help in raising segmental revenue growth.
Incontinence Neuromodulation Market by Region
Based on region, the global incontinence neuromodulation market is segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa.
North America dominated the incontinence neuromodulation market with the largest revenue share in 2022. There has been a significant increase in the prevalence of urinary and fecal incontinence in North America due to factors such as the aging population, obesity, and diabetes. This has led to a higher demand for incontinence neuromodulation treatments. According to the International Continence Society in the U.S., the prevalence of urinary incontinence among community-dwelling adult women was 62%, and 32% of adult women experienced urinary incontinence at least monthly. The development of new and advanced neuromodulation devices and therapies has improved the safety, effectiveness, and ease of use of incontinence neuromodulation treatments, leading to increased adoption by healthcare providers and patients. There is growing awareness and acceptance of incontinence neuromodulation treatments among healthcare providers and patients in North America. This is due to the effectiveness and safety of these treatments and the increasing availability of information and educational resources. The increasing healthcare expenditure in North America has resulted in improved access to healthcare services, including incontinence neuromodulation treatments. This has led to a higher demand for these treatments and has supported the market’s revenue growth.
Incontinence Neuromodulation Competitive Landscape
The prominent players operating in the global incontinence neuromodulation market are:
Incontinence Neuromodulation Strategic Developments
The expected size of the global incontinence neuromodulation market in 2031 is US$ 3.04 billion.
Asia Pacific is the key growth region in the global incontinence neuromodulation market due to the surge in incontinence neuromodulation industry trends in China, Japan, and the Indian subcontinent.
The global incontinence neuromodulation market is expected to register a revenue CAGR of 11.2%.
The urinary incontinence segment dominates the global incontinence neuromodulation market with a sizable revenue share.
The high costs of incontinence neuromodulation and side effects related to incontinence neuromodulation are major factors restraining the market revenue growth to its full potential.
*Insights on financial performance are subject to the availability of information in the public domain